abacavir + lamivudine




Zuellig Pharma
Concise Prescribing Info
Abacavir 600 mg, lamivudine 300 mg
Dosage/Direction for Use
Adult, adolescent & childn (at least 25 kg) 1 tab once daily.
May be taken with or without food.
Special Precautions
Hypersensitivity. Discontinue use in patients w/ HLA-B* 507 allele. Pancreatitis; immune reactivation syndrome. Risk of virological failure; osteonecrosis; MI. Opportunistic infections & other complications of HIV infection. Periodic monitoring of liver function test & HBV replication markers upon discontinuation in patients co-infected w/ HBV. Triple nucleoside therapy. Not recommended in combination of lamivudine w/ cladribine. Allergic reactions due to azo colouring agent. Not recommended in renal & moderate or severe hepatic impairment; preexisting liver dysfunction. Pregnancy & lactation. Mitochondrial dysfunction in HIV -ve infants exposed in utero &/or post-natally to nucleoside analogues. Childn <25 kg. Elderly >65 yr.
Adverse Reactions
Headache; nausea, vomiting, diarrhoea; rash; fever, fatigue. Abacavir: Hypersensitivity; anorexia; lethargy. Lamivudine: Insomnia; cough, nasal symptoms; abdominal pain or cramps; alopecia; arthralgia, muscle disorders; malaise.
Drug Interactions
Abacavir: Decreased plasma conc w/ rifampicin, phenobarb, phenytoin. Decreased Cmax w/ methadone. Lamivudine: Increased AUC w/ co-trimoxazole, ethanol. Inhibited intracellular phosphorylation of cladribine.
MIMS Class
ATC Classification
J05AR02 - lamivudine and abacavir ; Belongs to the class of antivirals for treatment of HIV infections, combinations.
Kivexa FC tab 600 mg/300 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in